Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.6% – Here’s Why

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) shares dropped 0.6% on Thursday . The company traded as low as $0.80 and last traded at $0.87. Approximately 82,238 shares traded hands during trading, an increase of 27% from the average daily volume of 64,574 shares. The stock had previously closed at $0.87.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Processa Pharmaceuticals in a research note on Thursday, December 5th.

Processa Pharmaceuticals Stock Down 0.6 %

The business has a fifty day moving average of $0.99 and a 200 day moving average of $1.31. The firm has a market cap of $2.83 million, a P/E ratio of -0.26 and a beta of 0.62.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.